Clinical Support Services for the NIAMS Intramural Research Program

NIAMS 校内研究项目的临床支持服务

• 批准号: 10492975
• 负责人: Robert Colbert
• 金额: $ 1045.48万
• 依托单位: NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10492975
• 关键词: Adult-Onset Still' s Disease; Agonist; Ambulatory Care Facilities; Ankylosing spondylitis; Appointments and Schedules; Arthritis; Autoimmune; Blood Vessels; COVID-19; Clinical; Clinical Protocols; Clinical Research; Contracts; Databases; Dermatologic; Dermatology; Dermatomyositis; Disease; Double-Blind Method; Enrollment; Evaluation; Fellowship; Frequencies; Functional disorder; Genetic; Genetic Determinism; Genomics; Glucocorticoids; Hospitalists; IgG1; Immune; Inflammatory; Infrastructure; Institutional Review Boards; Intramural Research Program; Investigation; Janus kinase; Longitudinal Studies; Lupus; Mediating; Medical; Medicare; Melorheostosis; Molecular; Monoclonal Antibodies; Myopathy; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Natural History; Neighborhood Health Center; Nurse Practitioners; Nursing Research; Oral; Orthopedic Procedures; Outcome; PPAR gamma; Pathogenesis; Pathogenicity; Patients; Peroxisome Proliferator-Activated Receptors; Phase; Phase Ib Clinical Trial; Physicians; Preparation; Prevention; Prospective Studies; Protocols documentation; Randomized; Research Activity; Research Assistant; Research Infrastructure; Research Support; Rheumatism; Rheumatoid Arthritis; Rheumatology; Role; Safety; Services; Severities; Specimen; Spinal Fusion; Spondylarthritis; Syndrome; Systemic Lupus Erythematosus; TNF gene; Training Programs; Translational Research; Travel; Treatment Protocols; United States National Institutes of Health; Vasculitis; anakinra; autoinflammatory; beneficiary; chronic graft versus host disease; clinical center; congenital immunodeficiency; coronavirus disease; cost; efficacy validation; immunoregulation; kinase inhibitor; minority communities; omalizumab; open label; phase 2 study; placebo controlled study; programs; skin disorder; standard care; systemic autoimmune disease; systemic juvenile idiopathic arthritis; therapeutic evaluation

This project has provided research infrastructure support for the following clinical protocols as noted: 03-AR-0173: Studies of the Natural History, Pathogenesis and Outcome in Autoimmune and Inflammatory Diseases Including Juvenile Dermatomyositis 11-AR-0223: Studies on the Natural History and Pathogenesis of Spondyloarthritis 12-AR-8001: Compassionate Use Treatment Protocol 14V-MC-JAGA Treatment of Autoinflammatory Syndromes Expected to Benefit from JAK 1/2 Inhibition 18-AR-0081: Investigation of the Natural History, Genetics and Pathophysiology of Systemic Juvenile Idiopathic Arthritis and Adult-onset Still's Disease and Related Inflammatory Conditions 91-AR-0196: Studies on the Natural History and Pathogenesis of Polymyositis, Dermatomyositis, and Related Diseases 00-AR-0222: Studies of the Pathogenesis and Natural History of Arthritis and Related Conditions 01-AR-0227: Natural History of Rheumatic Disease in Minority Communities 14-AR-0200: Studies of the Natural History, Pathogenesis and Outcome of Idiopathic Systemic Vasculitis 15-AR-0165: Study of the Natural History, Pathogenesis and Outcome of Melorheostosis-a Rare Osteosclerotic Disease 07-AR-0146: Analysis of Stored Identified Specimens from Patients Enrolled in Protocol Number 98-AR-0150 99-AR-0004: Molecular Basis of Primary Immunodeficiencies 15-AR-0185: Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus; a Phase Ib Clinical Trial and Associated Mechanistic Studies 15-AR-0060: The Role of PPAR-gamma Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE). 94-AR-0066: Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE) 03-AR-0131: Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study 04-AR-0205: Progression of Spinal Fusion in Ankylosing Spondylitis 13-AR-0056: Stopping Anti-TNF Agents in Rheumatoid Arthritis (STARA) Trial 15-AR-N010: Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries 96-AR-0102: Standard Care Dermatology; Evaluation and treatment of subjects with dermatologic diseases 18-AR-0035: Topical ruxolitinib in cGVHD; Phase II study of topical ruxolitinib for cutaneious chronic graft versus host disease (cGVHD) 13-AR-0071: Anakinra in Pustular Dermatoses; A phase 2 study of anakinra in inflammatory pustular dermatoses: evaluation of therapeutic efficacy and validation of pathogenic mechanisms 20-AR-0046: Phase 2 Zilucoplan in IMNM (Andrew Mammen); A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of Zilucoplan in subjects with immune-mediated necrotizing myopathy 000207: SAD-COVID: The natural history of coronavirus disease (COVID-19) in systemic autoimmune diseases; an observational prospective study 20-AR-0032: Glucocorticoid Genomics in SLE; Genomic effects of glucocorticoids in patients with systemic lupus erythematosus 13-AR-0005: STOP LUPUS: A phase 1b, randomized, double-blind, placebo controlled study with an open label extension to evaluate the safety and tolerability of Omalizumab, a humanized IgG1 monoclonal antibody in patients with lupus (STOP LUPUS)

该项目为以下临床方案提供了研究基础设施支持： 03-AR-0173：自身免疫性和炎症性疾病的自然病史，发病机理和结局的研究 11-AR-0223：关于脊椎关节炎的自然病史和发病机理的研究 8001年12月12日：富有同情心的治疗方案14V-MC-JAGA治疗自身炎症综合征的治疗方法预计将受益于JAK 1/2抑制 20081年18月18日：全身少年特发性关节炎和成人疾病的自然史，遗传学和病理生理学的研究 91-AR-0196：关于多肌炎，皮肤炎和相关疾病的自然病史和发病机理的研究 00-AR-0222：关节炎和相关条件的发病机理和自然病史的研究 01-AR-0227：少数民族疾病的自然历史 14-AR-0200：对特发性全身血管炎的自然病史，发病机理和结果的研究 15-AR-0165：对情绪低落的自然病史，发病机理和结局的研究 07-AR-0146：分析列出的识别标本的标本，该标本是98-AR-0150 99-ar-0004：原发性免疫缺陷的分子基础 0185年1月15日：在全身性红斑狼疮的口服Janus激酶抑制剂Tofacitinib的安全性； IB期临床试验和相关机理研究 15-ar-0060：PPAR-GAMMA激动剂在SLE（PPAR-SLE）中的免疫调节和血管预防中的作用。 94-ar-0066：全身性红斑狼疮的发病机理和自然历史研究（SLE） 03-AR-0131：强直性脊柱炎严重程度的遗传决定因素 - 纵向研究 04-AR-0205：强直性脊柱炎的脊柱融合进展 13-ar-0056：在类风湿关节炎（Stara）试验中停止抗TNF药物 15-AR-N010：Medicare受益人主要骨科手术的频率和并发症 96-AR-0102：标准护理皮肤病学；评估和治疗皮肤病学疾病的受试者 20035年18月18日：CGVHD中的局部ruxolitinib;局部鲁唑替尼的第二阶段研究，用于皮肤慢性移植与宿主疾病（CGVHD） 13-ar-0071：脓疱性皮肤病的Anakinra； Anakinra在炎症性脓疱性皮肤上的2阶段研究：评估治疗功效和致病机制的验证 20046年20月20日：IMNM中的2阶段Zilucoplan（Andrew Mammen）；第二阶段，多中心，随机，双盲，安慰剂对照研究，以评估Zilucoplan在免疫介导的坏死性肌病的受试者中的安全性，耐受性和功效 000207：悲伤：全身自身免疫性疾病中冠状病毒病的自然史（Covid-19）；观察性的前瞻性研究 20032年20月20日：SLE中的糖皮质激素基因组学；糖皮质激素对全身性红斑狼疮患者的基因组作用 13-ar-0005：停止狼疮：1B期，随机，双盲，安慰剂对照研究，带有开放式标签扩展，以评估狼疮患者中人源化的IgG1 IgG1单克隆抗体的安全性和耐受性（停止卢普斯（Stop Lupus））